v3.24.0.1
Equity-Method Investment and Other Investments - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Oct. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jul. 30, 2021
Schedule of Equity Method Investments [Line Items]          
Equity method investment   $ 11,765 $ 32,455    
Loss from equity method investments   (15,633) (11,079) $ (1,325)  
AvenCell [Member]          
Schedule of Equity Method Investments [Line Items]          
Equity method investment   11,800 32,500    
Investment Owned, Fair Value         $ 62,900
Loss from equity method investments   6,600 11,400 2,900  
Investments in and Advances to Affiliates, at Fair Value, Gross Reductions   14,100 14,300 $ 1,800  
Sparing Vision [Member]          
Schedule of Equity Method Investments [Line Items]          
Investment Owned, Fair Value $ 14,800 14,800 14,800    
Sparing Vision [Member] | Series A2 Preferred Stock [Member]          
Schedule of Equity Method Investments [Line Items]          
Number of preferred stock received 83,316        
Kyverna Therapeutics Inc [Member]          
Schedule of Equity Method Investments [Line Items]          
Investment Owned, Fair Value   $ 10,000 $ 10,000    
Kyverna Therapeutics Inc [Member] | Series B Preferred Stock [Member]          
Schedule of Equity Method Investments [Line Items]          
Number of preferred stock received   3,739,515      
Fair value of stock received   $ 7,000      
Number of stock additionally invested   1,602,649      
Cash consideration received on sale of common stock   $ 3,000      
Joint Venture AvenCell [Member] | AvenCell [Member]          
Schedule of Equity Method Investments [Line Items]          
Equity Method Investment, Ownership Percentage   33.33%      
Preferred Stock Purchase Agreement [Member] | Joint Venture AvenCell [Member] | AvenCell [Member]          
Schedule of Equity Method Investments [Line Items]          
Equity Method Investment, Ownership Percentage         33.33%
Preferred Stock Purchase Agreement [Member] | Joint Venture AvenCell [Member] | Cellex and BXLS [Member]          
Schedule of Equity Method Investments [Line Items]          
Equity Method Investment, Ownership Percentage         66.67%